|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Children (aged ≤ 18 years) who underwent total thyroidectomy for neoplasm or RET germline mutation at our institution between 1997 and 2018 were included.
|
31686157 |
2020 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Multiple endocrine neoplasia type 2 (MEN2) is an autosomal dominant genetic disease caused by RET gene germline mutations that is characterized by medullary thyroid carcinoma (MTC) associated with other endocrine tumors.
|
30763276 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
A tissue microarray (TMA) was constructed from tumor specimens in triplicate and stained by immunohistochemistry for RET, phospho-MEK, MAPK(dpERK), PPARγ, and phospho-AKT(pAKT).
|
30552739 |
2019 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
We describe a case of papillary thyroid carcinoma with fibromatosis/fasciitis-like stroma (PTC-FLS) that contained the rare BRAF c.1799_1801delTGA (p.V600_K601delinsE) mutation, which has not previously been reported in this tumour, as well as the CTNNB1 c.133T>C (p.S45P) mutation.
|
31327063 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
ALK and RET Inhibitors Promote HLA Class I Antigen Presentation and Unmask New Antigens within the Tumor Immunopeptidome.
|
31540894 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Incidence of bilateral tumors is high and increases with the number of tumor foci in multifocal PTC.
|
30851890 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Of 16 patients assayed known to harbor anALK, ROS1, or RET in tumor, G360 detected fusions in 7 cases, ctDx-Lung detected fusions in 13 cases, and 3 cases were detected by neither.
|
31320002 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
With the development of a new class of RET-specific tyrosine kinase inhibitors, which appear to have particularly strong activity against RET gene rearranged tumours, there is now considerable interest in identifying RET gene rearrangements across a wide range of cancers.
|
31558784 |
2019 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Next generation sequencing (NGS) of paired tumor and peripheral blood revealed a germline pathogenic RET mutation, indicating the hereditary nature of MTC in this patient.
|
31409511 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Furthermore, RET and HER2 inhibition in a PDX model of BrM led to a statistically significant antitumor response vs control (n = 4, % tumor growth inhibition [mean difference; SD], anti-RET = 86.3% [1176; 258.3], P < .001; anti-HER2 = 91.2% [1114; 257.9], P < .01).
|
29961873 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Spindle Cell Tumors With RET Gene Fusions Exhibit a Morphologic Spectrum Akin to Tumors With NTRK Gene Fusions.
|
31219820 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Cabozantinib, an orally bioavailable tyrosine kinase inhibitor with activity against MET, vascular endothelial growth factor receptor 2, AXL, ROS1, and RET was assessed in patients with non-small-cell lung carcinoma (NSCLC) as part of a phase II randomized discontinuation trial with cohorts from 9 tumor types.
|
30528315 |
2019 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
MEN1 is characterized by the occurrence of parathyroid, enteropancreatic, and pituitary tumors; MEN2A is characterized by medullary thyroid carcinoma and pheochromocytoma, and MEN4 is characterized by a pathological spectrum similar to that of MEN1 in association with tumors of the adrenal, kidney, and reproductive organs.
|
30641519 |
2019 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
TERT promoter mutations correlated with older age (P < 0.0001), larger tumor size (P = 0.0002), oxyntic and aggressive PTC variants (P = 0.01), higher tumor stages (P < 0.0001), distant metastases (<0.0001) and disease outcome (P < 0.0001).
|
31042674 |
2019 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Furthermore, in vivo study revealed that overexpression of miR-15a inhibited tumor growth via downregulating the levels of RET and phosphorylated AKT.
|
31496725 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
However, further molecular testing with Archer fusion assay revealed a novel NCOA4-RET gene fusion, adding it to the list of multiple kinase fusions originally reported in these tumors.
|
30938880 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Although the t(12;15) (p13;q25) translocation resulting in an ETV6-NTRK3 gene fusion is well documented, advances in molecular profiling in salivary gland tumors have led to the discovery of RET as another ETV6 gene fusion partner in SC.
|
30130630 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
<b>Methods:</b> Here, we investigated the impact of PTC-209, a small-molecule Bmi-1 inhibitor, on human cancer cell viability alone and in combination with anticancer drugs, namely, cisplatin, oxaliplatin, 5-fluorouracil, camptothecin, and Frondoside-A and its impact on cellular migration and colony growth <i>in vitro</i> and on tumor growth <i>in ovo</i>.
|
31695609 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Expression analysis of ANKRD26 and RET was performed for the tumor harboring ANKRD26-RET, for corresponding normal thyroid tissue and PTC tumors with representative genetic alterations (BRAFV600E, CCDC6-RET), complemented by a comparative search in the "UniProt" database.
|
31425920 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
<b>Results:</b> Both MR<sub>glc</sub> and SUV<sub>max</sub> were significantly higher for hereditary cluster 1 (<i>SDHx, VHL</i>) tumors than for hereditary cluster 2 (<i>RET, NF1</i>) and sporadic tumors (<i>P</i> < 0.01 and <i>P</i> < 0.05, respectively).
|
30413658 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In this report a further case of SV-PTC is described which was associated to Hashimoto's thyroiditis, a finding never described in the cytological literature up to now for SV-PTC; this association created further differential diagnostic problems.The neoplasm displayed RET-PTC1 fusion.
|
30659000 |
2019 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
RET mutations have been associated with tumor proliferation, invasion, and migration.
|
31715421 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Extended analysis confirmed the presence of a somatic MTC-related retrocopy of RET in both sporadic and hereditary tumors.
|
31288802 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
To investigate the role of cytoneme-mediated signaling as a mechanism for distributing growth factor signaling proteins between tumor and tumor-associated cells, we analyzed EGFR and RET Drosophila tumor models and tested several genetic loss-of-function conditions that impair cytoneme-mediated signaling.
|
31568500 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
These fusions and RET amplification can induce transformation of non-tumorigenic cells, support xenograft tumor formation, and render sensitivity to RET inhibition.
|
30446652 |
2018 |